Press Briefing Day 2 - SATURDAY, JUNE 16, 2018

A new anti-CD22 CAR-T immunotherapy saved the lives of children with leukemia
Dr Jing Pan, Beijing Boren Hospital, Beijing, China (Abstract S832)


Our study shows that CD22-CAR-T cell therapy is a highly effective and safe treatment option for pediatric r/r B-ALL patients even after they failed CD19-CAR-T therapy and also-HCT. It gives these otherwise untreatable patients a new hope.MAIN SLIDES

iNNOVATE Study: Ibrutinib plus Rituximab for patients with Waldenström’s Macroglobulinemia
Dr Meletios Dimopoulos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece (Abstract S852)

Based on the data from this study, ibrutinib+rituximab could become a standard treatment option for WM. MAIN SLIDES

Answering the unmet need in one of the most common types of lymphoma: It’s as simple as A-D-C
Dr Laurie H. Sehn, BC Cancer Agency, Vancouver, Canada (Abstract S802)

Based on these results, polatuzumab vedotin has been granted Breakthrough Therapy Designation by the US Food and Drug Administration and PRIME (PRIority MEdicines) designation by the European Medicines Agency for R/R DLBCL. MAIN SLIDES

EHA Topics-in-Focus: Making CAR-T cells happen in Europe
John Gribben, Barts Cancer Institute, London, United Kingdom

EHA Topics-in-Focus: From the basics of sickle cell disease to where we are now
Maria Cappellini, University of Milan-Foundation IRCCS Policlinico Hospital, Italy